Aldosterone as a mediator in cardiovascular injury

Cardiology in Review

Volumn 10, Issue 2, 2002, Pages 97-107

  Stier Jr , Charles T ^a   Chander, Praveen N ^a   Rocha, Ricardo ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Aldosterone; Aldosterone antagonists; Cardiovascular disease; Hypertension; Thrombotic microangiography

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CAPTOPRIL; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; NITRIC OXIDE; RENIN; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CATECHOLAMINE RELEASE; CONGESTIVE HEART FAILURE; CORRELATION ANALYSIS; DRUG ANTAGONISM; ELECTROLYTE BALANCE; FLUID BALANCE; HEART ARRHYTHMIA; HEART MUSCLE FIBROSIS; HEART MUSCLE NECROSIS; HYPERTENSION; MORTALITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE;

EID: 0036127046     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045415-200203000-00008     Document Type: Article

References (57)

1. Spironolactone in the management of congestive cardiac failure: A review
2. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
3. Non-epithelial effects of aldosterone
4. Evidence for the presence in arterial walls of intracellular-molecular mechanism for action of mineralocorticoids
5. Mineralocorticoid binding in cultured smooth muscle cells and fibroblasts from rat aorta
6. Aldosterone and dexamethasone binding in human arterial smooth muscle cells
7. High affinity aldosterone binding sites (type 1 receptors) in rat heart
8. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor
9. Prerequisite for cardiac aldosterone action
10. Myocardial production of aldosterone and corticosterone in the rat: Physiologic regulation
11. Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology
12. Complete prevention of cerebral accidents in malignant hypertension
13. Malignant hypertension produced by treatment with desoxycorticosterone acetate and sodium chloride
14. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: Role of renin and sodium in vascular changes
15. Effect of angiotensin II blockade on renal injury in mineralocorticoid-salt hypertension
16. Clinical characteristics of primary aldosteronism from an analysis of 145 cases
17. Primary hyperaldosteronism in essential hypertensives: Prevalence, biochemical profile and molecular biology
18. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect
19. Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats
20. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats
21. Aldosterone modulates plasminogen activator inhibitor-1 and glomemlosclerosis in vivo
22. Vasculoprotective effect of a selective aldosterone receptor antagonist in stroke-prone hypertensive rats
23. Eplerenone, a new selective aldosterone receptor antagonist (SARA): Efficacy in patients with mild to moderate hypertension
24. The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction
25. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats
26. The role of blood pressure and aldosterone in the production of hemorrhagic stroke in captopriltreated hypertensive rats
27. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
28. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study
29. Remodeling of the right and left ventricles in experimental hypertension
30. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states
31. Biological determinants of aldosterone-induced cardiac fbrosis in rats
32. Fibrosis of tria and great vessels in response to angiotensin II or aldosterone infusion
33. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension
34. Left ventricular fibrosis in renovascular hypertensive rats: Effect of losartan and spironolactone
35. Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts
36. Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts?
37. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy
38. + channels
39. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats
40. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients
41. Aldosterone blockade reduces collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients
42. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES)
43. Death in ventricular fibrillation induced by isoproterenol in DOCA-salt pretreated rats preceded by changes in myocardial electrolytes
44. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease
45. The inotropic action of d-aldosterone on papillary muscles isolated from monkeys
46. Role of endotheliumderived nitric oxide in the regulation of cardiac oxygen metabolism: Implications in health and disease
47. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1β
48. Influence of adrenalectomy and steroid replacement on heart citrate synthase levels
49. Potassium's cardiovascular protective mechanisms
50. Increased superoxide anion generation and altered vasoreactivity in rabbits on low-potassium diet
51. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt
52. Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide
53. Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure
54. Endothelium-dependent vasodilation is attenuated in patients with heart failure
55. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure
56. Selective aldosterone receptor antagonism improves endothelial function in diet induced atherosclerosis
57. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production